CD4 and plasma cell myeloma: An IgG-based BCMA-T cell bispecific antibody (EM801) also increased CD3+ T cell/myeloma cell crosslinking, followed by CD4+/CD8+ T cell activation, and secretion of interferon-gamma, granzyme B, and perforin A [101].